Compare Nike Inc (NKE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Nike Inc trades at $35.04 (market cap $52.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Nike Inc is far larger — about 7× Spyre Therapeutics Inc. Common Stock's market cap, and Nike Inc pays a 4.64% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| NKE | SYRE | |
|---|---|---|
Market Cap | $52.48B | $7.52B |
Volume | 30,189,626 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $108.92 |
52-Week Low | $33.87 | $22.18 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.18B | $6.52B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $35.35, up 1.84% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from declining revenue ($46.31B in 2025 vs. $51.4B in 2024) and compressed margins (net margin 6.74%), though valuation appears reasonable with P/E of 16.9. Analyst consensus remains mixed with 47% buy ratings but a $36.80 price target suggesting limited upside. Recent news highlights inventory challenges and China market pressures.
Nike's turnaround strategy focuses on inventory discipline and digital DTC growth, but execution risks persist amid weak consumer demand. The stock offers moderate value at current levels with dividend support, though revenue stabilization is critical for sustained recovery. Near-term catalysts include Q4 2026 earnings on June 30, 2026.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
